Duplicate Document
This document appears to be a copy. The original version is:
Capital Markets Overview for Public Cannabis Companies (2017)Capital Markets Overview for Public Cannabis Companies (2017)
Capital Markets Overview for Public Cannabis Companies (2017) The passage provides aggregate financing data and market listings for cannabis‑related public companies, but it contains no specific allegations, transactions, or individuals that suggest misconduct or high‑level influence. It is largely descriptive industry data, offering limited investigative value. Key insights: US cannabis firms raised $1.35 bn across 78 deals in the 12‑month period ending Sep 30 2017.; Canada contributed $1.056 bn of that capital; Australia $26 m.; Four cannabis firms traded on Nasdaq, one REIT on NYSE, two on NYSE American, and >200 on OTC markets.
Summary
Capital Markets Overview for Public Cannabis Companies (2017) The passage provides aggregate financing data and market listings for cannabis‑related public companies, but it contains no specific allegations, transactions, or individuals that suggest misconduct or high‑level influence. It is largely descriptive industry data, offering limited investigative value. Key insights: US cannabis firms raised $1.35 bn across 78 deals in the 12‑month period ending Sep 30 2017.; Canada contributed $1.056 bn of that capital; Australia $26 m.; Four cannabis firms traded on Nasdaq, one REIT on NYSE, two on NYSE American, and >200 on OTC markets.
Tags
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.